Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ExpreS2ion Biotech Holding AB's revenue for the
three
months ended in Mar. 2026 was kr1.04 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was kr3.36 Mil.
ExpreS2ion Biotech Holding AB's Revenue per Share for the
three
months ended in Mar. 2026 was kr0.01.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.24.
Warning Sign:
ExpreS2ion Biotech Holding AB revenue per share has been in decline for the last 5 years.
During the past 13 years, ExpreS2ion Biotech Holding AB's highest 3-Year average Revenue per Share Growth Rate was 19.60% per year. The lowest was -54.20% per year. And the median was -37.80% per year.
ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
ExpreS2ion Biotech Holding AB Revenue Related Terms
ExpreS2ion Biotech Holding AB Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:EXPRS2 vs VRTX, REGN, ALNY: Revenue Comparison
For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ExpreS2ion Biotech Holding AB Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's Revenue distribution charts can be found below:
* The bar in red indicates where ExpreS2ion Biotech Holding AB's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr3.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) has a Revenue of kr3.36 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on ExpreS2ion Biotech Holding AB and its competitors.
Is ExpreS2ion Biotech Holding AB's Revenue too high?
ExpreS2ion Biotech Holding AB's current Revenue is kr3.36 Mil. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's Revenue compare to VRTX and REGN?
ExpreS2ion Biotech Holding AB's Revenue of kr3.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on ExpreS2ion Biotech Holding AB and its competitors. ExpreS2ion Biotech Holding AB's current Revenue is kr3.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) is currently considered Possible Value Trap. The stock's GF Value™ is kr3.42, compared to a current price of kr1.43 — trading 58.2% below its estimated fair value. The current Revenue is kr3.36 Mil. ExpreS2ion Biotech Holding AB's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (OSTO:EXPRS2), the current Revenue is kr3.36 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Overvalued in 2026?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued.
The current stock price of kr1.43 is trading 58.2% below its estimated GF Value™ of kr3.42.
GuruFocus considers ExpreS2ion Biotech Holding AB to be Possible Value Trap.
Key valuation signals for OSTO:EXPRS2:
Revenue: kr3.36 Mil
GF Value™: kr3.42 vs. price of kr1.43 (58.2% below fair value)
No single metric tells the full story. See the OSTO:EXPRS2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ExpreS2ion Biotech Holding AB Business Description
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
43GF Score
Get the complete analysis for OSTO:EXPRS2
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EXPRS2 has been successfully added to your 
